Acne Drugs Global Market Report 2024

Acne medications encompass pharmaceutical solutions designed to address issues related to acne scarring, blackheads, whiteheads, and more severe forms of the condition. These drugs operate by either targeting bacterial infections or reducing edema and oil production. Typically, a timeframe of four to eight weeks is required before prescription acne medications demonstrate efficacy. Complete resolution of acne may extend over several months or even years.

The primary categories of acne drugs include inflammatory and non-inflammatory variants. Inflammatory acne drugs are employed for the treatment of mild to moderate inflammatory acne. Key therapeutic classes comprise retinoids, antibiotics, salicylic acid, and benzoyl peroxide. These medications find application across various end-user segments, including hospitals, clinics, pharmacies, drug stores, and ambulatory surgical centers.

The acne drugs market research report is one of a series of new reports from The Business Research Company that provides acne drugs market statistics, including acne drugs industry global market size, regional shares, competitors with an acne drugs market share, detailed acne drugs market segments, market trends and opportunities, and any further data you may need to thrive in the acne drugs industry. This acne drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acne drugs market size has grown steadily in recent years. It will grow from $5.84 billion in 2023 to $6.11 billion in 2024 at a compound annual growth rate (CAGR) of 4.6%. The growth observed in the historical period can be ascribed to several factors, including the escalating prevalence of acne, a growing population, robust economic expansion, an upswing in pharmaceutical spending, increased disposable income, and a rise in healthcare expenditure.

The acne drugs market size is expected to see steady growth in the next few years. It will grow to $7.3 billion in 2028 at a compound annual growth rate (CAGR) of 4.5%. The anticipated growth in the forecast period can be linked to accelerated economic expansion, heightened healthcare expenditure, the substantial potential of emerging economies, a rising teenage population, and the prevalence of sedentary lifestyles. Noteworthy trends expected in the forecast period involve strategic investments in narrow-spectrum antibiotics, the formulation of combination therapies for acne treatment, financial commitments in cannabis products, particularly those containing cannabis oil, partnerships for the development of novel drugs, and leveraging social media platforms for the marketing of acne treatment products.

The acne drug market is significantly influenced by the rise in people's disposable income, serving as a major driving force. The escalation in disposable income typically mirrors an improved economy, resulting in augmented wages and salaries, consequently amplifying healthcare spending. According to the Bureau of Economic Analysis, disposable personal income surged by $7.3 billion in July 2023. This upsurge in disposable income, coupled with amplified expenditure on facial care products, is anticipated to persist, thereby fueling market growth during the forecast period.

The escalating prevalence of acne is projected to be a key driver propelling the growth of the acne drug market in the foreseeable future. Acne, a skin condition arising from clogged pores due to oil and dead skin cells, prompts individuals to seek remedies. Acne drugs function by mitigating inflammation, reducing oil production, and preventing pore blockage, ultimately enhancing the appearance of acne-prone skin. With nearly 90% of the global population affected by some form of acne, the condition poses a widespread challenge. In the United States alone, approximately 12 million individuals struggle with severe acne, which, if untreated, can result in skin scarring. Consequently, a significant portion of the population invests in acne care drugs and products to manage the condition. Hence, the mounting prevalence of acne stands as a substantial driver catalyzing growth within the acne drug market.

The latest trend shaping the acne drug market is the adoption of combination therapy, involving the simultaneous use of two drugs with distinct mechanisms of action. Such combinations exhibit enhanced efficacy and improved adherence compared to monotherapy, which involves using a single drug in isolation. This approach combines a topical retinoid drug, effective in unclogging pores, with an antimicrobial drug utilized for treating infections in acne management. Examples of combination therapy include products such as Epiduo, Acanya, Ziana, and Benzamycin, manufactured by Galderma, Allergan, Medicis, and Atrix, respectively.

Leading companies operating in the acne drug market are actively engaged in developing advanced receptor inhibitor drugs and broadening their research into treatment advancements to gain a competitive edge in the burgeoning healthcare sector. Advanced receptor inhibitor drugs function by blocking the activity of specific receptors within the body. For instance, in September 2023, Sun Pharmaceutical Industries Ltd., an India-based biopharmaceutical company, introduced (PR)WINLEVI (clascoterone cream 1% w/w). WINLEVI is formulated to mitigate the effects of acne hormones on the skin by disrupting the androgen cascade, departing from the topical approach in acne treatment that targets follicular hyperkeratinization, inflammation reduction, or antibacterial properties. While the precise mechanism of action of WINLEVI remains under study, it aims to suppress androgen receptor activities within sebaceous gland cells, thereby reducing sebum (oil) production and inflammatory cytokines associated with acne.

In December 2021, the pharmaceutical and healthcare giant Sanofi S.A., headquartered in France and renowned for its expertise in drug development and commercialization, successfully acquired Origimm Biotechnology GmbH for an undisclosed sum. This strategic move by Sanofi aims to bolster its vaccine research and development (R&D) pipeline, enhance its proficiency in skin microbiome and skin immunology, and broaden its array of treatment options for acne. Furthermore, as a result of this acquisition, Sanofi is poised to extend the reach of these innovative products to encompass the entire European market. Origimm Biotechnology GmbH, based in Austria, is a pioneering pharmaceutical company known for its advancements in identifying pathogenic components of the skin microbiome and bacterial antigens responsible for skin diseases.

Major companies operating in the acne drugs market report are Johnson & Johnson, Galderma S.A., Almirall SA, Bausch Health Companies Inc., GlaxoSmithKline, Reckitt Benckiser Group, Mayne Pharma Group Limited, Allergan Plc., Cipher Pharmaceuticals, Sol Gel Advanced Topical Therapy, Pfizer Inc., Novartis AG, Merck & Co. Inc., Amgen Inc., Abbott, AstraZeneca, Eli Lilly and Company, Daiichi Sankyo Company Limited, Sinopharm Group Co. Ltd., Mylan N.V., F. Hoffmann-La Roche Ltd., Bayer AG, Teva Pharmaceutical Industries, Sun Pharmaceutical Industries Ltd., Allergan, Cipla Inc., Zydus Cadila, Otsuka Pharmaceutical Co. Ltd., Shanghai Pharmaceuticals Holding Co. Ltd., Jiangsu Hengrui Medicine, Guangzhou Baiyunshan Pharmaceutical, China Meheco Co Ltd., Huadong Medicine Co. Ltd., Pfizer Inc., Galderma S.A., Amgen Europe B.V., Roche Holding AG, Ranbaxy Laboratories, Stiefel Laboratories, BIOCAD, Zentiva (Sanofi), Gedeon Richter PLC, Polpharma SA Pharmaceutical Works, Egis Group, Dermira Inc., Bausch Health Companies Inc., Estee Lauder Inc., Nimue Skincare International.

North America was the largest region in the acne drugs market in 2023. The Middle East is expected to be the largest growing region in the global acne drugs market during the forecast period. The regions covered in the acne drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the acne drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The acne drugs market consists of sales of retinoids, antibiotics, and diapsone. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acne Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acne drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acne drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acne drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Inflammatory Acne Drugs; Non-Inflammatory Acne Drugs
• 2) By Therapeutic Class: Retinoids; Antibiotics; Salicylic Acid; Benzoyl Peroxide; Other Therapeutics
• 3) By End User: Hospitals & Clinics; Pharmacies & Drug Stores; Other End Users
• Companies Mentioned: Johnson & Johnson; Galderma S.A.; Almirall SA; Bausch Health Companies Inc.; GlaxoSmithKline
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.